Skip to main content
OpenTrials
Completed

NCT Number: NCT05590039

Study To Evaluate The Safety And Efficacy Of The MyEllevate® Procedure

The intended purpose of the MyEllevate® procedure used in this study is to assess the safety and efficacy of the procedure for soft tissue approximation and elevation of sub dermis and underlying muscle of the submentum & jawline.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

New Jersey Plastic Surgery, Montclair, New Jersey, United States

Loading trial locations.

About this study

Subjects are to be enrolled in this clinical study if they are a healthy male or female between the age of 18 - 65. Up to 10 subjects will be enrolled at 2 study centers. All subjects will attend a screening/pre-procedure visit which may be performed on the same day as the procedure visit but no more than 30 days prior to their procedure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A healthy male or female between the age of 18 - 65.
  • Must have any or all the following: visible platysma bands, glands and/or sagging in the submentum, jawline and/or neck.
  • Reads and understands English.
  • Understands and accepts obligation not to receive any other procedures on the treatment area through the length of the study.
  • Understands and accepts the obligation and is logistically able to be present for all visits.
  • Is willing to comply with all requirements of the study and sign the informed consent document.

Exclusion criteria

Is pregnant or of childbearing potential and not using medically effective birth control, or has been pregnant in the last 3 months, currently breast feeding or planning a pregnancy during the study.

  • Is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within in the area to be treated 6 months (or at the discretion of the Investigator) prior to entering this study.
  • Have received any treatments or procedures (including injectables such as Botox or fillers) in the area to be treated at least 4 months prior to treatment.
  • Take antiplatelets, anticoagulants, thrombolytics, or anti-inflammatories.
  • Have an active localized or systemic infection.
  • Have an open wound in area being treated.
  • Have a significant systemic illness or an illness localized in area being treated.
  • Have had recent surgeries or problems in the treatment area (e.g. neck fracture, neck sprain, pinched nerve, spondylosis, arthritis in the neck).
  • Have a history of thrombophlebitis.
  • Have a history of heart failure or kidney disease.
  • Have a history of allergic reaction or intolerance to the anesthesia used during the procedure.
  • Have a history of poor wound healing.
  • Have a history of poor circulation.
  • Have a systemic autoimmune disease known to impair wound healing.
  • Have a history of keloid formation.
  • Currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within the area to be treated 6 months (or at the discretion of the Investigator) prior to entering this study.
  • Has any condition or is in a situation which in the investigators opinion may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation.

Treatment and study plan

MyEllevate Procedure

Device

The defined study area will be identified and may be marked with a surgical marker.

A local tumescent anesthetic, such as lidocaine, will be injected to the area prior to the procedure. The MyEllevate® device will be used in accordance with the Instructions for Use (IFU) manual for soft tissue approximation and elevation of sub dermis and underlying muscle of the submentum and jawline.

Primary outcomes

  1. Physician Global Aesthetic Improvement Score (PGAIS)

    Time frame: 30 days post last treatment

    The physician will grade the improvement that they see at the 30 day follow up (30 days post treatment). They will grade them as one of the following: Very Much Improved, Much Improved, Improved, No Change, or Worsened.

Sponsors and collaborators

Lead sponsor

Cynosure, Inc.

Industry

Registry information

Official study title

Prospective Clinical Study To Evaluate The Safety And Efficacy Of The MyEllevate® Procedure

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Oct 21, 2022
Registry last updated
Aug 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.